Pharmacokinetics of a new long acting endectocide formulation containing 2.25% ivermectin and 1.25% abamectin in cattle

17Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.

Abstract

The objective of this study was to determine the kinetic parameters of a new formulation that contained 2.25% ivermectin combined with 1.25% abamectin in bovine plasma. The results for 2.25% ivermectin: Cmax (37.11 ng/mL ± 7.42), Tmax (16 days ± 5.29), T1/2 (44.62 days ± 53.89), AUC (928.2 ng·day/mL ± 153.83) and MRT (36.73 days ± 33.64), and for 1.25% abamectin: Cmax (28.70 ng/mL ± 9.54), Tmax (14 days ± 4.04), T1/2 (15.40 days ± 11.43), AUC (618.05 ng·day/mL ± 80.27) and MRT (20.79 days ± 8.43) suggest that this combination of 2.25% ivermectin + 1.25% abamectin possesses properties that give this pharmaceutical formula a longer activity time than two of the commercial products tested (1% ivermectin and 1% abamectin), and showed similarity to 3.15% ivermectin. © 2007 The Authors.

Cite

CITATION STYLE

APA

Borges, F. A., Cho, H. S., Santos, E., Oliveira, G. P., & Costa, A. J. (2007). Pharmacokinetics of a new long acting endectocide formulation containing 2.25% ivermectin and 1.25% abamectin in cattle. Journal of Veterinary Pharmacology and Therapeutics, 30(1), 62–67. https://doi.org/10.1111/j.1365-2885.2007.00816.x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free